研究单位：[1]Eisai Co.,Ltd.[2]The First People's Hospital of Yunnan Province Kunming,Yunnan,China,650032[3]Tong Ren Hospital Shanghai Jiaotong University School of Medicine Shanghai,Shanghai,China,200050[4]Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine Shanghai,Shanghai,China,200052[5]The Affiliated Hospital of Qingdao University Qingdao,Shandong,China,266000[6]The First Affiliated Hospital of Dalian Medical University Dalian,Liaoning,China,116011[7]Dalian Municipal Central Hospital Affiliated of Dalian Medical University Dalian,Liaoning,China,116021[8]The Second Hospital of Dalian Medical University Dalian,Liaoning,China,116023
The primary purpose of the study is to confirm the efficacy of dotinurad 4 milligram (mg) to febuxostat 40 mg on the percentage of participants achieving a serum uric acid (SUA) level less than or equal to (<=) 6.0 milligrams per deciliter (mg/dL) at Week 24 in Chinese participants with gout.
